Separate terms with OR to return results that match either term.
 
Clear All
9,752 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00703-3301-04 00703-3301 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
00703-3311-01 00703-3311 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
00703-3311-04 00703-3311 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Nov. 14, 2005 In Use
00781-3164-75 00781-3164 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct. 21, 1988 Oct. 31, 2016 In Use
00781-3165-75 00781-3165 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct. 21, 1988 Nov. 30, 2016 In Use
00781-3167-71 00781-3167 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 4, 2014 Feb. 4, 2014 In Use
00781-3167-95 00781-3167 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 4, 2014 Feb. 4, 2014 In Use
00781-3168-71 00781-3168 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 4, 2014 Feb. 4, 2014 In Use
00781-3168-95 00781-3168 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 4, 2014 Feb. 14, 2014 In Use
67457-0239-00 67457-0239 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 12, 2013 In Use
67457-0239-01 67457-0239 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 1, 2011 In Use
76135-0005-01 76135-0005 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous Jan. 1, 2019 In Use
76135-0006-01 76135-0006 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous Jan. 1, 2019 In Use
67457-0245-00 67457-0245 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 12, 2013 In Use
67457-0245-01 67457-0245 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 1, 2011 In Use
67457-0246-00 67457-0246 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 12, 2013 In Use
67457-0246-01 67457-0246 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 1, 2011 In Use
23155-0685-31 23155-0685 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 25, 2022 In Use
23155-0686-31 23155-0686 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 25, 2022 In Use
25021-0463-01 25021-0463 Octreotide acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 31, 2022 In Use
25021-0464-01 25021-0464 Octreotide acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 31, 2022 In Use
25021-0465-01 25021-0465 Octreotide acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 31, 2022 In Use
25021-0466-05 25021-0466 Octreotide acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 31, 2022 In Use
25021-0467-05 25021-0467 Octreotide acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 31, 2022 In Use
63323-0376-01 63323-0376 OCTREOTIDE ACETATE Octreotide 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0376-04 63323-0376 OCTREOTIDE ACETATE Octreotide 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0377-01 63323-0377 OCTREOTIDE ACETATE Octreotide 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0377-04 63323-0377 OCTREOTIDE ACETATE Octreotide 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0378-05 63323-0378 OCTREOTIDE ACETATE Octreotide 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0379-05 63323-0379 OCTREOTIDE ACETATE Octreotide 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0365-01 63323-0365 OCTREOTIDE ACETATE Octreotide 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 June 30, 2017 No Longer Used
63323-0365-04 63323-0365 OCTREOTIDE ACETATE Octreotide 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 June 30, 2017 No Longer Used
16729-0332-03 16729-0332 OXALIPLATIN OXALIPLATIN 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 17, 2018 In Use
16729-0332-05 16729-0332 OXALIPLATIN OXALIPLATIN 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 17, 2018 In Use
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous March 18, 2022 In Use
00003-3734-13 00003-3734 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec. 8, 2017 In Use
00003-3756-14 00003-3756 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug. 30, 2021 In Use
59572-0730-07 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0730-14 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
59572-0740-07 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0740-14 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
35356-0679-10 35356-0679 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 June 30, 2019 In Use
35356-0679-30 35356-0679 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 June 30, 2019 In Use
51655-0800-04 51655-0800 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 30, 2014 In Use
67457-0769-02 67457-0769 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 31, 2017 In Use
64679-0726-01 64679-0726 ondansetron hydrochloride ONDANSETRON HYDROCHLORIDE 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 27, 2006 In Use
64679-0727-01 64679-0727 ondansetron hydrochloride ONDANSETRON HYDROCHLORIDE 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 27, 2006 In Use
51662-1539-01 51662-1539 ONDANSETRON ONDANSETRON 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 6, 2021 In Use
00404-9930-02 00404-9930 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Jan. 13, 2022 In Use
51662-1245-01 51662-1245 ONDANSETRON ONDANSETRON 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sept. 23, 2018 In Use

Found 9,752 results in 15 milliseconds — Export these results